From OpenAI’s offices to a deal with Eli Lilly — how Chai Discovery became one of the flashiest names in AI drug development
- Jan 17
- 1 min read
Drug discovery, the art of identifying new molecules to develop pharmaceuticals, is a notoriously time-consuming and difficult process.
Traditional techniques, like high-throughput screening, offer an expensive scattershot approach — one that is not often successful. However, a new breed of biotech companies are leveraging AI and advanced data technologies in an attempt to accelerate and streamline the process.
Chai Discovery, an AI startup founded in 2024, is one such company. In a little over 12 months, its young co-founders have managed to raise hundreds of millions of dollars and rally the backing of some of Silicon Valley’s most influential investors, making it one of the flashiest firms in a growing industry.
Read the full story | TechCrunch
